Mikhail Blagosklonny – Oncology Professor and the Publisher of Peer-Review Journal (Oncotarget)
Mikhail Blagosklonny is an Oncology professor based at the Roswell Park Cancer Institute and his main work is to do research on Aging and Cancer. Blagosklonny attended the First Pavlov State Medical University (St. Petersburg) where he pursued an MD in Internal Medicine. He also studied Ph.D in Cardiology and Experimental Medicine from the same institution. In 2002, he was chosen the medicine associate professor at New York Medical College before filling a position at Ordway Research Institute, Albany, New York as the Senior Scientist. Blagosklonny held that position until 2009, the time he was selected the Oncology professor at Roswell Park Cancer Institute. Blagosklonny interests in research entail cancer and targeted therapies in cancer (treatment that protect ordinary cells from the damage) in addition to anti-aging drugs and the underlying aging mechanisms (biogerontology)
Blagosklonny has a hypothesis formulated regarding the possible roles of TOR signaling in Cancer and Aging and suggested utilizing of rapamycin, the common cancer drug as the possible life extension treatment. He is termed as among the key passionate advocates rapamycin within longevity research. Blagosklonny is also the partner of Cancer Biology & Therapy Editor, and additionally plays role in the editorial board of Cell Death & Differentiation.
Utilizing of Rapamycin was brought about by Blagosklonny. The medication is generally utilized in treating cancer. He has also been named among the numerous energetic promoters of Rapamycin in his life span research. Blagosklonny study works involved different tasks and covered cellular biology, molecular and clinical studies. His reviews for the most part involve ontogenesis, flag transduction, medication resistance (for ordinary cells and selected protection), cell cycle, tumor suppressors, anticancer therapeutics, apoptosis and mitosis.
Mikhail Blagosklonny has additionally expounded on aging hyperfunction hypothesis and still explores on chemotherapeutic mechanisms and cell cyclotherapy, being well recognized for his unmistakable enthusiasm for Oncology. He has the conviction and interest of getting fulfilling results for cancer and aging. Blagosklonny unequivocally trusts cancer is a treatable issue and that is the major reason he proposed utilization of Rapamycin. Of late, Blagosklonny possesses 300 research articles, audits and book sections distributed under his name. He is likewise a partner of several different associations. View Mikhail’s profile on Google Scholar